New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy

Marek Cena, Frances Karam, Rajesh Ramineni, Wissam Khalife, Alejandro Barbagelata

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The new percutaneous Impella CP (Cardiac Power; Abiomed, Inc., Danvers, MA) was designed to provide a higher level of support than Impella 2.5 (Abiomed, Inc.). We present the first documented case of a patient that was transitioned from the Impella 2.5 to Impella CP. A 48-year-old male patient with no medical history was transferred to our institution with a one day history of worsening shortness of breath. The patient was unstable and found to have monomorphic ventricular tachycardia at 220 beats/min that was cardioverted to normal sinus rhythm. An emergent right and left heart catheterization was performed showing nonobstructive coronary artery disease, biventricular failure with a left ventricular ejection fraction (LVEF) of 5 to 10%, high pulmonary capillary wedge pressure (PCWP) 22 mm Hg, right atrial (RA) pressure 22 mm Hg, and a very low cardiac index of 1.0 L/min/m2. Because of severe cardiogenic shock, Impella 2.5 was inserted providing flow up to 2.1 L/min; however, the patient remained unstable and critically ill with severe multiorgan failure. To provide better mechanical support, the device was upgraded to the new Impella CP that can provide up to 3.5 L/min of cardiac output. Over the course of the next 72 hours, the patient showed significant improvement in hemodynamics and cardiac function (LVEF 45%), with recovery of liver function. The Impella CP was removed with no complications. The new Impella CP was shown to be safe and effective for prolonged use in critically ill patients and may significantly improve their prognosis.

Original languageEnglish (US)
Pages (from-to)258-262
Number of pages5
JournalInternational Journal of Angiology
Volume25
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Cardiogenic Shock
Cardiomyopathies
Equipment and Supplies
Critical Illness
Stroke Volume
Pulmonary Wedge Pressure
Atrial Pressure
Recovery of Function
Ventricular Tachycardia
Cardiac Catheterization
Cardiac Output
Dyspnea
Coronary Artery Disease
Hemodynamics
Liver

Keywords

  • cardiogenic shock
  • Impella CP
  • nonischemic cardiomyopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy. / Cena, Marek; Karam, Frances; Ramineni, Rajesh; Khalife, Wissam; Barbagelata, Alejandro.

In: International Journal of Angiology, Vol. 25, No. 4, 01.12.2016, p. 258-262.

Research output: Contribution to journalArticle

Cena, Marek ; Karam, Frances ; Ramineni, Rajesh ; Khalife, Wissam ; Barbagelata, Alejandro. / New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy. In: International Journal of Angiology. 2016 ; Vol. 25, No. 4. pp. 258-262.
@article{30ad225301104eb2ad7453661bbebdc9,
title = "New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy",
abstract = "The new percutaneous Impella CP (Cardiac Power; Abiomed, Inc., Danvers, MA) was designed to provide a higher level of support than Impella 2.5 (Abiomed, Inc.). We present the first documented case of a patient that was transitioned from the Impella 2.5 to Impella CP. A 48-year-old male patient with no medical history was transferred to our institution with a one day history of worsening shortness of breath. The patient was unstable and found to have monomorphic ventricular tachycardia at 220 beats/min that was cardioverted to normal sinus rhythm. An emergent right and left heart catheterization was performed showing nonobstructive coronary artery disease, biventricular failure with a left ventricular ejection fraction (LVEF) of 5 to 10{\%}, high pulmonary capillary wedge pressure (PCWP) 22 mm Hg, right atrial (RA) pressure 22 mm Hg, and a very low cardiac index of 1.0 L/min/m2. Because of severe cardiogenic shock, Impella 2.5 was inserted providing flow up to 2.1 L/min; however, the patient remained unstable and critically ill with severe multiorgan failure. To provide better mechanical support, the device was upgraded to the new Impella CP that can provide up to 3.5 L/min of cardiac output. Over the course of the next 72 hours, the patient showed significant improvement in hemodynamics and cardiac function (LVEF 45{\%}), with recovery of liver function. The Impella CP was removed with no complications. The new Impella CP was shown to be safe and effective for prolonged use in critically ill patients and may significantly improve their prognosis.",
keywords = "cardiogenic shock, Impella CP, nonischemic cardiomyopathy",
author = "Marek Cena and Frances Karam and Rajesh Ramineni and Wissam Khalife and Alejandro Barbagelata",
year = "2016",
month = "12",
day = "1",
doi = "10.1055/s-0034-1384822",
language = "English (US)",
volume = "25",
pages = "258--262",
journal = "International Journal of Angiology",
issn = "1061-1711",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - New impella cardiac power device used in patient with cardiogenic shock due to nonischemic cardiomyopathy

AU - Cena, Marek

AU - Karam, Frances

AU - Ramineni, Rajesh

AU - Khalife, Wissam

AU - Barbagelata, Alejandro

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The new percutaneous Impella CP (Cardiac Power; Abiomed, Inc., Danvers, MA) was designed to provide a higher level of support than Impella 2.5 (Abiomed, Inc.). We present the first documented case of a patient that was transitioned from the Impella 2.5 to Impella CP. A 48-year-old male patient with no medical history was transferred to our institution with a one day history of worsening shortness of breath. The patient was unstable and found to have monomorphic ventricular tachycardia at 220 beats/min that was cardioverted to normal sinus rhythm. An emergent right and left heart catheterization was performed showing nonobstructive coronary artery disease, biventricular failure with a left ventricular ejection fraction (LVEF) of 5 to 10%, high pulmonary capillary wedge pressure (PCWP) 22 mm Hg, right atrial (RA) pressure 22 mm Hg, and a very low cardiac index of 1.0 L/min/m2. Because of severe cardiogenic shock, Impella 2.5 was inserted providing flow up to 2.1 L/min; however, the patient remained unstable and critically ill with severe multiorgan failure. To provide better mechanical support, the device was upgraded to the new Impella CP that can provide up to 3.5 L/min of cardiac output. Over the course of the next 72 hours, the patient showed significant improvement in hemodynamics and cardiac function (LVEF 45%), with recovery of liver function. The Impella CP was removed with no complications. The new Impella CP was shown to be safe and effective for prolonged use in critically ill patients and may significantly improve their prognosis.

AB - The new percutaneous Impella CP (Cardiac Power; Abiomed, Inc., Danvers, MA) was designed to provide a higher level of support than Impella 2.5 (Abiomed, Inc.). We present the first documented case of a patient that was transitioned from the Impella 2.5 to Impella CP. A 48-year-old male patient with no medical history was transferred to our institution with a one day history of worsening shortness of breath. The patient was unstable and found to have monomorphic ventricular tachycardia at 220 beats/min that was cardioverted to normal sinus rhythm. An emergent right and left heart catheterization was performed showing nonobstructive coronary artery disease, biventricular failure with a left ventricular ejection fraction (LVEF) of 5 to 10%, high pulmonary capillary wedge pressure (PCWP) 22 mm Hg, right atrial (RA) pressure 22 mm Hg, and a very low cardiac index of 1.0 L/min/m2. Because of severe cardiogenic shock, Impella 2.5 was inserted providing flow up to 2.1 L/min; however, the patient remained unstable and critically ill with severe multiorgan failure. To provide better mechanical support, the device was upgraded to the new Impella CP that can provide up to 3.5 L/min of cardiac output. Over the course of the next 72 hours, the patient showed significant improvement in hemodynamics and cardiac function (LVEF 45%), with recovery of liver function. The Impella CP was removed with no complications. The new Impella CP was shown to be safe and effective for prolonged use in critically ill patients and may significantly improve their prognosis.

KW - cardiogenic shock

KW - Impella CP

KW - nonischemic cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=84996538090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996538090&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1384822

DO - 10.1055/s-0034-1384822

M3 - Article

AN - SCOPUS:84996538090

VL - 25

SP - 258

EP - 262

JO - International Journal of Angiology

JF - International Journal of Angiology

SN - 1061-1711

IS - 4

ER -